StreetInsider.com News Articles

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Tue, 18 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26945226.html

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Tue, 18 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26945226.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931900.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931900.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 14 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26931245.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 14 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26931245.html

H.C. Wainwright Reiterates Buy Rating on Tscan Therapeutics Inc (TCRX)

Thu, 13 Aug 2026 07:00:07 -0400

H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $7.00 price target on Tscan Therapeutics Inc (NASDAQ: TCRX).

The analyst commented: "With promising initial data from Cohort C in hand, TScan heads into the Phase 3 ALLOHA-2 study with a validated, commercial ready manufacturing process. Of the 14 evaluable patients in the Phase 1 Cohort C ALLOHA-1 study, 13 (93%) responded with declining recipient chimerism and 11 (79%) achieved complete donor chimerism within 3 weeks of their first TSC-101 infusion, with 2 of the 3 remaining patients approaching complete donor chimerism by data cut off. These results were generated

TScan Therapeutics, Inc. (TCRX) Tops Q2 EPS by 3c

Wed, 12 Aug 2026 07:43:39 -0400

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $1.88 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

Form 10-Q TScan Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908946.html

Form 10-Q TScan Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908946.html

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26908850.html

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26908850.html

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 07:00:00 -0400

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028

Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process

Cash and cash equivalents fund operations into the second quarter of 2027

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended June 30, 2026, and

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 07:00:00 -0400

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028

Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process

Cash and cash equivalents fund operations into the second quarter of 2027

TScan doses first patient in phase 3 trial for blood cancer therapy

Wed, 29 Jul 2026 07:00:18 -0400

TScan Therapeutics (Nasdaq: TCRX) announced that the first patient has been dosed in its pivotal Phase 3 ALLOHA-2 trial evaluating TSC-101, a T cell receptor-engineered T cell therapy, in patients with acute myeloid leukemia and myelodysplastic syndromes.

The patient, enrolled in June, received an infusion of TSC-101 following successful stem cell engraftment. The trial investigates TSC-101's efficacy and safety in treating residual disease to prevent relapse following allogeneic hematopoietic cell transplantation. The company anticipates topline data from the trial in mid-2028.

The Phase 3 trial compares TSC-101 administered after standard-of-care hematopoietic cell transplantation versus transplantation alone. Patient assignment to treatment or control

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

Wed, 29 Jul 2026 07:00:00 -0400

Actively enrolling patients across the US with anticipated topline data readout mid-2028

WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2™ trial (NCT07702578). The patient, who was enrolled in June, has now received their first infusion of TSC-101 following successful stem cell engraftment. The trial is investigating the efficacy and safety of TSC-101

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

Wed, 29 Jul 2026 07:00:00 -0400

Actively enrolling patients across the US with anticipated topline data readout mid-2028

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Wed, 24 Jun 2026 07:00:00 -0400

WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 4^th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026 at 11:30 a.m. Eastern Time.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Wed, 24 Jun 2026 07:00:00 -0400

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An

H.C. Wainwright Reiterates Buy Rating on Tscan Therapeutics Inc (TCRX)

Tue, 23 Jun 2026 06:54:11 -0400

H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $7.00 price target on Tscan Therapeutics Inc (NASDAQ: TCRX).

The analyst commented: "Yesterday, TScan released interim Cohort C data from the ALLOHA trial that addressed key questions on the new commercial-ready manufacturing process and provided additional visibility into the registrational ALLOHA-2 Phase 3 design. Of the 14 evaluable patients, 13 (93%) responded with decreasing recipient chimerism and 11 (79%) achieved complete donor chimerism within ~3 weeks of their first TSC-101 infusion, with 2 of the remaining 3 patients approaching complete donor chimerism at data cutoff. Importantly, these results were generated

Form 8-K TScan Therapeutics, Inc. For: Jun 22

Mon, 22 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260622/26669812.html

Form 8-K TScan Therapeutics, Inc. For: Jun 22

Mon, 22 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260622/26669812.html

TScan reports early Phase 1 data showing chimerism gains with TSC-101

Mon, 22 Jun 2026 07:00:14 -0400

TScan Therapeutics (Nasdaq: TCRX) reported initial data from Cohort C of its ALLOHA Phase 1 study evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.

Of 19 patients enrolled in Cohort C, 14 proceeded to transplant and received a first infusion of TSC-101. Eleven of those 14 patients achieved complete donor chimerism within approximately three weeks of their first infusion. Two of the remaining three patients showed improving chimerism. All five patients assessed after a second infusion showed complete donor chimerism.

The company reported a manufacturing success rate of approximately 90%, or 17 of 19 patients, using its commercial-ready

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Trans

Mon, 22 Jun 2026 07:00:00 -0400

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101

TSC-101 continues to be well-tolerated

Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study of TSC-101 this month

Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., today, June 22, at 8:30 a.m. ET

WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Trans

Mon, 22 Jun 2026 07:00:00 -0400

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101

TSC-101 continues to be well-tolerated

Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study of TSC-101 this month

Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., today, June 22, at 8:30 a.m. ET

WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the